National Stem Cell Centre to Present Vision of How the Centre Will Impact the Future of Human Health at Boston Biorelationships 2004
CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 2, 2004-- Stephen Livesey, Chief Scientific Officer and Dianna DeVore, Chief Operating Officer of the Australian National Stem Cell Centre will present to an audience of U.S. biotech investors and entrepreneurs this week at the Boston Biorelationships 2004 Conference at the Royal Sonesta Hotel in Cambridge, MA. The event is part sponsored by Invest Australia (North America offices), Australia’s national investment attraction agency.
Invest Australia’s Investment Director of Biotechnology and Pharmaceuticals Helen Hill will be meeting with key industry figures to discuss stem cell and clinical trial capabilities in Australia.
DeVore points out that “The Australian National Stem Cell Centre is uniquely placed to capture the benefits of Australia’s stem cell and related research through its novel company model, internationally renowned scientists and innovative commercialization strategy.”
The Australian National Stem Cell Centre received an additional US$ 55 million for the period 2006-2011 in the Australian Government’s recent budget.
According to Livesey the stability provided by the long term funding to 2011 has had immediate benefits: “We have been able to elaborate a long term vision to provide real benefits in the field of regenerative medicine through our comprehensive research programs in the areas of haematopoesis and cardiac regeneration.”
“We’re honored to have Invest Australia and the Australian National Stem Cell Centre representatives here this week for Biorelationships 2004 and are thrilled to bring them together with our attendees and key influencers in the U.S. biotech community,” said Andrew Jeffery, conference host and President, ANZACC, New England.
About the Australian National Stem Cell Centre
The Australian National Stem Cell Centre (NSCC) (http://www.nscc.edu.au) is a major collaborative initiative uniting many of the country’s leading academic researchers to develop innovative therapeutic products to treat a range of debilitating diseases.
It was formed out of the ‘Backing Australia’s Ability’ initiative of the Australian Government as Australia’s Biotechnology Centre of Excellence and also benefits from a supporting grant from the Victorian State government under its Science, Technology and Innovation program.
Since its creation in 2002 the NSCC has recruited an experienced management team and built a research programme which combines expertise in four core platform technologies - embryonic stem cells, adult stem cells, tissue repair and immune modulation - to enable the creation and delivery of stem cell therapeutics. The areas of therapeutic focus are haematopoiesis, specifically bone marrow transplantation and the development of transfusible blood products, and cardiac regeneration.
About Invest Australia - USA
Invest Australia is Australia’s national inward investment agency, set up by the Australian Federal Government in 1997 to attract productive foreign direct investment into Australia to support sustainable industry growth and development. Invest Australia has investment advisory specialists in 11 locations around the world, including San Francisco and New York, to provide investors with on-the-ground support and investment advice. Since 1997 Invest Australia has helped a wide range of international businesses invest in Australia and, today, is currently working with companies on projects with potential investment in Australia of more than USD$60 billion.
About Boston Bio-Relationships
Boston Bio-Relationships (http://www.biorelationships.com), hosted by the Australian New Zealand American Chamber of Commerce in New England (http://www.anzacc.org) is a high-level biopharmaceutical business meeting that connects business executives from Australia, New Zealand and the USA.
-------------------------------------------------------------------------------- Contact:
For Media/Analyst Interviews:
Dateline Media
Alison Minaglia, 212-898-0428 NY
203-972-3170 New England
alison.minaglia@datelinemedia.com
--------------------------------------------------------------------------------
Source: Invest Australia
